Esophageal Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Esophageal Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 3 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| RADX | Radiopharm Theranostics, Ltd | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Aug 2026 | ≤ 11 d | 2026-07-17 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeNCT07663786observationalOverall survival (OS) among participants treated with first-line nivolumab | — | Active, not recruiting | 2026-10-01 | in 42 d | 2026-06-23 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-07-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Esophageal Cancer
most recently updated first89 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | Pfizer | $155.3B | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerNCT07392892Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator | Phase 2/3 | Recruiting | Biological: PF-08634404, Nivolumab · Drug: Chemotherapy | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma | 840 | 2026-05-14 | 2031-07-22 | in 1,797 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Phase 1 Study of PF-08046033 in Advanced Solid TumorsNCT07519655Type, incidence and severity of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046033 | Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma | 250 | 2026-04-08 | 2028-07-14 | in 694 d | 2026-08-17 |
| NXTC | NextCure, Inc. | $30M | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNCT05572684results2026-08-13Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Terminatedsponsor's stated reason: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Drug: NC410, pembrolizumab | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 97 | 2022-10-06 | 2025-04-30actual | — | 2026-08-13 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| 051910.KS | LG Chem | $13.7B | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNCT07752875Phase 1: Number of participants with dose-limiting toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: LG00313112 | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Pancreatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumor | 250 | 2026-12-01 | 2032-10-31 | in 2,264 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496 | Phase 1 | Recruiting | Drug: LY4257496, Standard of Care Anticancer Therapies · Diagnostic test: LY4257529 | Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms | 421 | 2025-08-06 | Apr 2030 | ≤ 1,349 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791Phase 1a: Percentage of Participants with Dose Limited Toxicity (DLT) Toxicities | Phase 1 | Recruiting | Drug: LY4337713 | Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma | 241 | 2025-10-22 | Jul 2028 | ≤ 711 d | 2026-08-06 |
| STRO | Sutro Biopharma, Inc. | $365M | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: STRO-004, Pembrolizumab | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer | 200 | 2025-11-07 | Dec 2027 | ≤ 498 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481Objective Response Rate (ORR) | Phase 1 | Active, not recruiting | Drug: ABBV-400, Itraconazole (ITZ), Bevacizumab | Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer | 302 | 2023-11-09 | Sep 2027 | ≤ 406 d | 2026-08-04 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)NCT06644781Overall Survival (OS) | Phase 3 | Recruiting | Drug: Ifinatamab deruxtecan, Docetaxel, Paclitaxel, Irinotecan hydrochloride (HCl) | Esophageal Squamous Cell Carcinoma | 510 | 2025-03-27 | 2028-06-01 | in 651 d | 2026-08-04 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | 2023-10-13 | Sep 2027 | ≤ 406 d | 2026-07-30 |
| AAPG | Ascentage Pharma Group Inc. | — | APG-2449 in Patients With Advanced Solid TumorsNCT03917043Maximum Tolerated Dose (MTD) | Phase 1 | Recruiting | Drug: APG-2449 | Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma | 165 | 2019-05-27 | Dec 2027 | ≤ 498 d | 2026-07-23 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046054, pembrolizumab | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma | 714 | 2022-10-25 | 2028-01-05 | in 503 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation | Phase 1 | Recruiting | Drug: PF-08046876 | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer | 310 | 2025-08-20 | 2028-07-08 | in 688 d | 2026-07-22 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| ONC | BeOne Medicines | $545.6B | A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesNCT07554521Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 2 | Recruiting | Drug: Tislelizumab, Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin, Leucovorin | Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma | 30 | 2026-04-30 | 2031-12-31 | in 1,959 d | 2026-07-22 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNCT06628310Progression-Free Survival (PFS) as Assessed by Investigator | Phase 2 | Active, not recruiting | Drug: Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma | 185 | 2024-12-13 | Oct 2030 | ≤ 1,533 d | 2026-07-21 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersNCT05152147Progression-free survival (PFS) by BICR | Phase 3 | Active, not recruiting | Drug: Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 920 | 2021-12-02 | 2026-07-31 | — | 2026-07-17 |
| RADX | Radiopharm Theranostics, Ltd | — | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Drug: RAD301 ([68Ga]-RAD301) | Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer | 9 | 2023-11-09 | Aug 2026 | ≤ 11 d | 2026-07-17 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2023-11-01 | 2027-02-28 | in 192 d | 2026-07-16 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | Drug: Zanidatamab | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression | 200 | 2025-01-14 | 2026-12-31 | in 133 d | 2026-07-10 |
| GILD | Gilead Sciences | $177.9B | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasNCT07546812Objective Response Rate (ORR) | Phase 2 | Recruiting | Drug: Denikitug, Nivolumab, Ramucirumab, Paclitaxel | HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma | 120 | Jul 2026 | Jan 2030 | ≤ 1,260 d | 2026-07-10 |
| IMNM | Immunome, Inc. | $3.1B | A Phase 1 Study of IM-1617 in Participants With Advanced CancerNCT07578571Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of adverse events (AEs) and serious adverse events (SAEs) | Phase 1 | Recruiting | Drug: IM-1617 | Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer | 175 | 2026-05-21 | Jan 2029 | ≤ 895 d | 2026-07-09 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 1,006 | 2020-06-08 | 2027-06-16 | in 300 d | 2026-07-06 |
| CATX | Perspective Therapeutics | $366M | Lead-212 PSV359 Therapy for Patients With Solid TumorsNCT06710756Determination of safety and tolerability of [203Pb]Pb-PSV359 | Phase 1/2 | Recruiting | Drug: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359 | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma | 112 | 2025-04-28 | 2028-01-31 | in 529 d | 2026-07-06 |
| AZN | AstraZeneca | — | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2NCT07431281Progression Free Survival (PFS) (Cohort 1 and Cohort 2) | Phase 3 | Recruiting | Drug: Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, Leucovorin | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 2,130 | 2026-02-03 | 2029-08-16 | in 1,092 d | 2026-07-01 |
| BMY | Bristol-Myers Squibb | $134.9B | Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeNCT07663786observationalOverall survival (OS) among participants treated with first-line nivolumab | — | Active, not recruiting | Drug: Nivolumab | Esophageal Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | 726 | 2025-10-09 | 2026-10-01 | in 42 d | 2026-06-23 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808Safety and tolerability of IDE034 in Part 1 dose escalation | Phase 1 | Recruiting | Drug: IDE034 | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer | 150 | 2026-02-24 | 2027-07-30 | in 344 d | 2026-06-18 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNCT06238479Phase 1a: To determine the recommended dose of LY4101174 | Phase 1 | Active, not recruiting | Drug: LY4101174 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 490 | 2024-03-05 | Mar 2027 | ≤ 223 d | 2026-05-22 |
| AZN | AstraZeneca | — | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCNCT04550260Progression free survival (PFS) per RECIST 1.1 as assessed by BICR | Phase 3 | Active, not recruiting | Drug: Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine · Radiation | Esophageal Squamous Cell Carcinoma | 640 | 2020-10-19 | 2027-06-30 | in 314 d | 2026-05-13 |
| ALXO | ALX Oncology Inc. | $288M | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsNCT07085091Phase 1a: Incidence of dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: ALX2004, ALX2004, ALX2004 | NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC) | 170 | 2025-08-18 | Jun 2027 | ≤ 314 d | 2026-05-12 |
| BMY | Bristol-Myers Squibb | $134.9B | Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in FranceNCT06504615observationalOverall survival (OS) | — | Active, not recruiting | Drug: nivolumab + chemotherapy | Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) | 208 | 2024-12-10 | 2028-08-31 | in 742 d | 2026-04-03 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1) | Phase 1/2 | Recruiting | Drug: 177Lu-BetaBart | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) | 61 | 2026-02-23 | Dec 2027 | ≤ 498 d | 2026-03-27 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersNCT04430738results2025-09-09Number of Participants With Renal Dose-Limiting Toxicities (DLTs): Phase 1b (Cohort 1A and 1B) | Phase 2 | Active, not recruiting | Drug: tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab | Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma | 40 | 2020-09-15 | 2024-07-31actual | — | 2026-02-24 |
| AZN | AstraZeneca | — | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid TumorsNCT06005493The number of patients with adverse events | Phase 1/2 | Recruiting | Drug: AZD5863 | Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma | 280 | 2023-07-11 | 2027-07-16 | in 330 d | 2026-02-24 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06560645Dose Limiting toxicity (DLT) of PRT7732 | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: PRT7732 | Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma | 42 | 2024-11-04 | 2026-01-28actual | — | 2026-02-02 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06682806Safety and tolerability of PRT3789 in combination with pembrolizumab as measured by incidence of DLTs (Part 1) | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: PRT3789, pembrolizumab | Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation | 6 | 2025-06-03 | 2026-01-23actual | — | 2026-02-02 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Study of KK2269 in Adult Participants With Solid TumorsNCT06266299Number of Subjects Experiencing Dose-limiting Toxicity | Phase 1 | Recruiting | Drug: KK2269, Docetaxel | Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Non Small Cell Lung Cancer | 101 | 2024-01-18 | Mar 2029 | ≤ 954 d | 2026-01-28 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsNCT06549816Number of participants with adverse events (AEs) | Phase 1 | Completed | Drug: sigvotatug vedotin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 6 | 2024-08-21 | 2025-11-18actual | — | 2025-12-15 |
| CRSP | CRISPR Therapeutics AG | $5.1B | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid TumorsNCT05795595Phase 1 (Dose Escalation): Incidence of adverse events | Phase 1/2 | Completed | Biological: CTX131 | Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma | 19 | 2023-03-13 | 2025-09-18actual | — | 2025-11-26 |
| TEM | Tempus AI | $8.6B | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsNCT05169437results2025-10-29Overall Response Rate (ORR) - Independent Central Review (ICR) | Phase 2 | Terminatedsponsor's stated reason: Recruitment challenges | Drug: Niraparib | Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer | 22 | 2022-03-15 | 2024-08-06actual | — | 2025-10-29 |
| INCY | Incyte Corporation | $24.7B | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesNCT03144661Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: Strategic Business Decision | Drug: INCB062079 | Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer, Ovarian Cancer, Solid Tumors | 25 | 2017-05-25 | 2020-06-10actual | — | 2025-10-21 |
| INCY | Incyte Corporation | $24.7B | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsNCT04272034Number of treatment-emergent adverse events | Phase 1 | Terminatedsponsor's stated reason: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision. | Drug: INCB099318 | Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, Basal Cell Carcinoma (Unresectable or Metastatic), Sarcomatoid Renal Cell Carcinoma, Clear Cell Ovarian or Endometrial Carcinoma, Anal Carcinoma, Squamous Cell Penile Carcinoma, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L) | 105 | 2021-03-26 | 2024-08-16actual | — | 2025-10-16 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesNCT04772989Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: AB308, Zimberelimab | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 94 | 2021-03-19 | 2025-08-25actual | — | 2025-08-28 |
| GH | Guardant Health, Inc. | $21.5B | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444observationalDistant Recurrence Free Interval (D-RFi) | — | Recruiting | Diagnostic test: Guardant Reveal | Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma | 2,020 | 2021-09-07 | Aug 2029 | ≤ 1,107 d | 2025-08-22 |
| BMY | Bristol-Myers Squibb | $134.9B | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerNCT02872116results2022-06-28Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5 | Phase 3 | Completed | Drug: Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil | Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma | 2,031 | 2016-10-12 | 2020-05-27actual | — | 2025-08-07 |
| INCY | Incyte Corporation | $24.7B | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsNCT04242199Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: INCB099280 | Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma | 182 | 2020-09-04 | 2024-08-29actual | — | 2025-07-14 |
| MDNAF | Medicenna Therapeutics, Inc. | $22M | A Beta-only IL-2 ImmunoTherapY StudyNCT05086692MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) | Phase 1/2 | Recruiting | Drug: MDNA11, Pembrolizumab (KEYTRUDA®) | Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer | 115 | 2021-08-27 | 2026-06-30 | — | 2025-07-09 |
| LLY | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | $1.15T | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)NCT05432193Treatment emergent adverse events | Phase 1 | Terminatedsponsor's stated reason: Business decision | Drug: [Ga-68]-PNT6555, [Lu-177]-PNT6555 | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma | 20 | 2022-07-13 | 2023-11-10actual | — | 2025-06-25 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-585 in Patients With Advanced MalignanciesNCT05788484Dose escalation: To determine the maximum tolerated dose of CDX-585 and to select the CDX-585 dose(s) for evaluation in tumor-specific expansion cohorts | Phase 1 | Completed | Drug: CDX-585 | Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors | 20 | 2023-05-11 | 2025-05-21actual | — | 2025-06-15 |
| BMY | Bristol-Myers Squibb | $134.9B | Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction CancerNCT06499298observationalParticipant disease-free survival (DFS) | — | Completed | Drug: Nivolumab | Esophageal Cancer, Gastroesophageal Junction Cancer | 64 | 2024-12-03 | 2025-04-16actual | — | 2025-05-31 |
| PFE | Pfizer | $155.3B | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.NCT04152018Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding | Phase 1 | Terminatedsponsor's stated reason: Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority. | Drug: PF-06940434, PF-06801591 | Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer | 85 | 2019-11-13 | 2024-12-10actual | — | 2025-05-28 |
| MGNX | MacroGenics | $261M | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction CancerNCT02689284results2022-08-04Number of Patients With Dose Limiting Toxicities | Phase 1/2 | Completed | Biological: Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab | Gastric Cancer, Stomach Cancer, Esophageal Cancer | 95 | Jan 2016 | Jan 2021actual | — | 2025-03-17 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerNCT03809624Frequency of adverse events of INBRX-105 | Phase 1 | Terminatedsponsor's stated reason: Program terminated due to lack of meaningful efficacy signal. | Drug: INBRX-105 - PDL1x41BB antibody, Pembrolizumab | Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma | 160 | 2019-01-30 | 2024-10-03actual | — | 2024-10-23 |
| BNTX | BioNTech SE | — | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract TumorsNCT04683939results2024-10-02Occurrence of Treatment-emergent Adverse Events (TEAEs) Within a Patient Including Grade ≥ 3, Serious, Fatal TEAE by Relationship | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BNT141, Nab-paclitaxel, Gemcitabine | Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer | 13 | 2022-01-18 | 2023-07-24actual | — | 2024-10-02 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal CancerNCT05780736observationalDisease-free Survival (DFS) | — | Terminatedsponsor's stated reason: A decision was made to terminate the study due to expected timelines associated with start-up, participant enrollment, ethics committee approval and data availability from the study. | — | Esophageal Carcinoma, Gastroesophageal Junction Carcinoma | 33 | 2023-08-04 | 2024-08-23actual | — | 2024-09-25 |
| ADCT | ADC Therapeutics S.A. | $131M | Study of ADCT-301 in Patients With Selected Advanced Solid TumorsNCT03621982results2024-06-13Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Terminatedsponsor's stated reason: Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study. | Drug: ADCT-301 · Biological: Pembrolizumab | Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer | 78 | 2018-11-09 | 2022-12-14actual | — | 2024-06-13 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesNCT03329950Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-1140, CDX-301, pembrolizumab, Chemotherapy | Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia | 132 | 2017-12-01 | 2022-09-13actual | — | 2024-03-28 |
| CTMX | CytomX Therapeutics | $739M | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCLNCT03543813The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-2029 as a monotherapy | Phase 1/2 | Completed | Drug: CX-2029 | Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer | 133 | 2018-06-15 | 2023-06-01actual | — | 2024-01-23 |
| LUCD | Lucid Diagnostics, Inc. | $199M | Lucid Registry StudyNCT05965999observationalAgreement between positive EsoGuard test results and upper endoscopy diagnosis (i.e., subjects with BE/EAC newly diagnosed by upper endoscopy) | — | Unknown status | Device: EsoCheck | Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia | 500 | 2023-04-11 | 2024-06-01 | — | 2023-07-28 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesNCT04440943Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-527 | Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors | 27 | 2020-08-04 | 2023-04-06actual | — | 2023-06-18 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT1419 in Patients With Advanced Solid TumorsNCT04837677Dose limiting toxicities (DLT) of PRT1419 | Phase 1 | Completed | Drug: PRT1419 | Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer | 26 | 2021-08-11 | 2023-02-06actual | — | 2023-03-15 |
| LUCD | Lucid Diagnostics, Inc. | $199M | Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BENCT04293458Primary Efficacy | Not applicable | Completed | Device: EsoGuard | Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia | 145 | 2020-02-28 | 2022-08-22actual | — | 2023-01-25 |
| LUCD | Lucid Diagnostics, Inc. | $199M | Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EACNCT04295811Primary Efficacy | Not applicable | Unknown status | Device: EsoGuard (lab assay) · Diagnostic test: Esophagogastroduodenoscopy | Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia | 470 | 2020-06-18 | Dec 2023 | — | 2023-01-25 |
| GOSS | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | $70M | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaNCT04060342Phase 1 Dose Escalation - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Drug: GB1275, nab-paclitaxel and gemcitabine, pembrolizumab | Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma | 61 | 2019-08-13 | 2022-04-11actual | — | 2022-08-18 |
| BSX | Boston Scientific Corporation | $73.1B | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal CancerNCT00573131results2014-05-16Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT | Phase 2 | Terminatedsponsor's stated reason: OncoGel did not show any impact on overall tumor response | Drug: OncoGel (Paclitaxel gel), cisplatin, 5-FU · Radiation: radiation therapy · Procedure: esophageal resection | Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma | 137 | Jan 2008 | Nov 2010actual | — | 2022-06-22 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United KingdomNCT04936399observationalDistribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Age | — | Completed | Biological: Nivolumab | Esophageal Squamous Cell Carcinoma | 87 | 2020-06-25 | 2021-12-03actual | — | 2022-05-25 |
| OGN | Organon and Co | $3.6B | Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)NCT01077817results2013-05-01observationalPercentage of Participants With Exposure to Study Drugs (Case-Cohort Analysis) | — | Completed | Drug: Alendronate, Etidronate, Ibandronate, Risedronate, Raloxifene | Esophageal Cancer, Squamous Cell Carcinoma, Adenocarcinoma | 684,815 | 2010-02-26 | 2012-02-16actual | — | 2022-02-03 |
| 4507.T | Shionogi | $15.7B | First-in-human Study of S-588210 (S-488210+S-488211)NCT04316689Number of Participants with Adverse Events | Phase 1 | Completed | Biological: S-488210, S-488211 | Lung Cancer, Head and Neck Cancer, Bladder Cancer, Esophageal Cancer, Mesothelioma | 10 | 2019-07-30 | 2021-09-22actual | — | 2022-01-26 |
| INCY | Incyte Corporation | $24.7B | A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesNCT03652077Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: INCAGN02390 | Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency | 40 | 2018-09-24 | 2021-08-18actual | — | 2021-11-15 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerNCT01631552results2021-04-06Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events | Phase 1/2 | Completed | Drug: Sacituzumab Govitecan-hziy (SG) | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | 515 | 2012-12-17 | 2019-03-01actual | — | 2021-08-12 |
| AZN | AstraZeneca | — | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsNCT02658214Laboratory findings (including: clinical chemistry, hematology, and urinalysis) | Phase 1 | Completed | Drug: paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin, nab-paclitaxel (paclitaxel-albumin) + carboplatin, oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid), nab-paclitaxel (paclitaxel-albumin) + gemcitabine, cisplatin + 5-fluorouracil (5FU) · Biological: durvalumab, tremelimumab | Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Esophagogastric Junction Neoplasms, Carcinoma, Pancreatic Ductal, Esophageal Squamous Cell Carcinoma | 32 | 2016-04-28 | 2019-11-14actual | — | 2020-08-20 |
| TGTX | TG Therapeutics, Inc. | $7.7B | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid TumorsNCT02574663Adverse events as a measure of safety and tolerability of TGR-1202 as a single agent and in combination in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab. | Phase 1 | Completed | Drug: TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin + Folinic acid + Fluorouracil, Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab | Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST) | 66 | 2015-09-11 | Aug 2018actual | — | 2019-10-02 |
| LLY | Eli Lilly and Company | $1.15T | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and NeckNCT01059643results2017-12-04Percentage of Participants With a Complete Response (CR) or Partial Response (PR) | Phase 2 | Completed | Drug: LY2523355, pegfilgrastim | Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cancer of Head and Neck | 103 | Apr 2011 | Dec 2012actual | — | 2019-09-18 |
| INO | Inovio Pharmaceuticals | $124M | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of RelapseNCT02960594Adverse events graded in accordance with "Common Terminology Criteria for Adverse Events (CTCAE)", NCI version 4.03 | Phase 1 | Completed | Biological: INO-1400, INO-9012, INO-1401 | Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma | 93 | Dec 2014 | 2018-11-09actual | — | 2018-11-19 |
| TRAW | Traws Pharma, Inc. | $8M | Oral Rigosertib for Squamous Cell CarcinomaNCT01807546Overall response rate | Phase 2 | Completed | Drug: rigosertib | Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Penile Squamous Cell Carcinoma | 64 | Mar 2013 | Mar 2015actual | — | 2017-06-26 |
| AMGN | Amgen | $229.9B | Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaNCT01444456results2014-08-15observationalPercentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL | — | Completed | — | Anemia, Breast Cancer, Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Solid Tumors, Bladder Cancer, Endometrial Cancer, Renal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer | 1,262 | Oct 2011 | Aug 2013actual | — | 2017-03-20 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal CancerNCT01246960results2014-10-08Progression-Free Survival (PFS) | Phase 2 | Completed | Biological: Ramucirumab · Drug: Placebo, Oxaliplatin, Leucovorin, 5-Fluorouracil | Stomach Cancer, Esophageal Cancer | 168 | Apr 2011 | Sep 2013actual | — | 2014-10-08 |
| AMGN | Amgen | $229.9B | Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced CancerNCT00101907results2014-03-20Participant Incidence of Adverse Events | Phase 1 | Terminatedsponsor's stated reason: Study terminated per recommendation of Data Review Team | Drug: AMG 706, Gemcitabine, Cisplatin · Biological: Panitumumab | Lung Cancer, Pancreatic Cancer, Esophageal Cancer | 41 | Dec 2004 | Jun 2007actual | — | 2014-03-20 |
| AMGN | Amgen | $229.9B | AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction CancerNCT00719550Progression free survival (PFS), as measured by RECIST per local review | Phase 1/2 | Completed | Drug: Capecitabine, Epirubicin, AMG 102, Cisplatin, Placebo | Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer | 130 | Feb 2009 | Nov 2010actual | — | 2013-12-05 |
| BMY | Bristol-Myers Squibb | $134.9B | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal CancerNCT00971841results2013-07-19Number of Adverse Events (AEs) Per Participant | Phase 2 | Completed | Drug: Paclitaxel | Esophageal Cancer | 1 | Mar 2008 | Apr 2012actual | — | 2013-07-26 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal AdenocarcinomasNCT00909402Use National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) to establish the MTD, Dose Limiting Toxicity (DLT(s)) and safety profile of BMS-833923 administered in combination with Cisplatin and Capecitabine | Phase 1 | Completed | Drug: BMS-833923, Cisplatin, Capecitabine | Stomach Neoplasms, Esophageal Neoplasms | 39 | Nov 2009 | Nov 2012actual | — | 2013-06-21 |
| BMY | Bristol-Myers Squibb | $134.9B | BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With ChemotherapyNCT00017043 | Phase 2 | Completed | Drug: ixabepilone | Esophageal Cancer, Gastric Cancer | — | Feb 2001 | Jan 2003actual | — | 2013-04-05 |
| 4568.T | Daiichi Sankyo | $31.7B | DX-8951f in Treating Patients With Metastatic Stomach CancerNCT00017212 | Phase 2 | Completed | Drug: exatecan mesylate | Esophageal Cancer, Gastric Cancer | — | Apr 2001 | Sep 2003actual | — | 2012-05-16 |
| MNKD | Mannkind Corporation | $1.3B | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.NCT00423254To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP | Phase 1 | Completed | Biological: PSMA/PRAME, PSMA/PRAME | Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma, Mesothelioma, Breast Carcinoma, Esophageal Carcinoma, Gastric Cancer, Pancreatic Carcinoma, Neuroendocrine Cancer, Liver Cancer, Gallbladder Cancer, Biliary Tract Cancer, Anal Carcinoma, Bone Sarcomas, Soft Tissue Sarcomas, Carcinoma of Unknown Origin, Primary | 12 | Feb 2007 | Sep 2009actual | — | 2010-08-03 |
| SNY | Sanofi | — | Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal CancerNCT00160030Percentage of patients having completed the full treatment and Endoscopic complete response rate | Phase 2 | Completed | Drug: FOLFOX 4, 5-FU / Cisplatin | Esophageal Neoplasms | 97 | Sep 2004 | Oct 2007actual | — | 2009-12-07 |
| SNY | Sanofi | — | Oxaliplatin in Esophagus Cancer (Advanced) 1st LineNCT00259402Efficacy endpoints include tumor response, progression free and overall survival. | Phase 2 | Completed | Drug: Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU) | Esophageal Neoplasms | 41 | Feb 2000 | Oct 2008actual | — | 2009-12-07 |
| BMY | Bristol-Myers Squibb | $134.9B | Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal CancerNCT00344552Overall response rate | Phase 2 | Completed | Drug: Paclitaxel | Esophageal Cancer | 53 | Jun 2006 | Mar 2008actual | — | 2009-11-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Esophageal Cancer is matched — 6 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Esophageal Cancer
- Esophageal Adenocarcinoma
- Esophageal Squamous Cell Carcinoma
- Esophageal Neoplasms
- Esophageal Carcinoma
- Esophageal Squamous Cell Carcinoma (ESCC)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Esophageal Cancer” (a text search, wider than this page)